GENERAL8 Sept 2026
Novartis faces third clinical-trial setback in a week as muscle drug fails
Novartis's experimental muscle drug, del-desiran, has failed in a clinical trial. This is the company's third setback in a week. News of the failure sent shares down as much as 10% in early Zurich trading. Del-desiran was the centerpiece of Novartis's $12 billion takeover of Avidity Biosciences. The year's share gain has shrunk to about 4%, behind rival Roche. Investors should watch for further updates.
Key Statutory Highlights
- Novartis's drug del-desiran failed in a clinical trial, making it the company's third setback in a week.
- The failure caused Novartis shares to fall as much as 10% in early Zurich trading.
- Del-desiran was the centerpiece of Novartis's $12 billion takeover of Avidity Biosciences.
Actionable Advice for Taxpayers / Founders:If you hold Novartis shares or invest in pharmaceutical stocks, monitor company announcements before making any portfolio change.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: